



AMP Announces Stock Option Grant

ERFURT and BERLIN, Germany, April 5th, 2021 – AMP Alternative Medical Products Inc. (Frankfurt: [C4TA](#), ISIN: CA0318961038) (CSE: [XCX](#)), a pharmaceutical supplier of medical cannabis to German pharmacies, announces that it has granted incentive stock options to purchase 340,000 common shares of the Company to an officer and employees in accordance with its stock option plan.

Each option vests immediately, has an exercise price of C\$0.50 per share and expires on September 8, 2022. Following the grant, the Company will have 3,054,500 options issued and outstanding, representing approximately 10% of the Company's shares outstanding.

About AMP

AMP Alternative Medical Products Inc. (formerly AMP German Cannabis Group Inc.) is a pharmaceutical narcotic supplier of medical cannabis to German pharmacies with offices in Erfurt and Berlin, Germany. AMP operates in accordance with the German Narcotic Drug Act (BtMG) and with the Free State of Thuringia, ensuring medical cannabis products imported by AMP from around the world and sold in Germany meets the European Union - Good Manufacturing Practice (EU-GMP) standard. AMP's nationwide sales team represent medical cannabis products brands from [Aphria](#), [Bedrocan](#) and [Little Green Pharma](#). Learn more at www.amp-eu.com.

The AMP Roundtable Series discusses issues about medical cannabis in Germany and is available as a podcast and video. In Episode #2, "Politics and Medical Cannabis in Germany" Dr. Wieland Schinnenburg, MdB (FDP), provides an up-to-date overview of the political issues and challenges facing the medical cannabis industry in Germany. Learn more at www.amp-eu.de/roundtable.

Investor contact:

Alex Blodgett, CEO and Director

investor@amp-eu.com

+1 236-833-1602 (Germany and North America)

Media contact:

Valeria Bravo, Corporate and Media Communications

vbb@amp-eu.de

+1 604-689-7533 (Germany and North America)

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accept responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements that are based on the Company's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guaranteeing of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

SOURCE AMP Alternative Medical Products Inc.